Trends in Immunotherapy

Case Report

Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer

Downloads

https://doi.org/10.24294/ti.v6.i1.1386
Nomizo, T., Yamamoto, H., Murayama, T., Fukata, H., Nakamura, Y., Sonomura, M., Okuno, A., Kanda, N., Watanabe, C., & Kita, H. (2022). Immune-related adverse events caused by combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab for lung cancer. Trends in Immunotherapy, 6(1). https://doi.org/10.24294/ti.v6.i1.1386
Volume 6 Issue 1 (2022)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Takashi Nomizo
    Department of Respiratory Medicine, Takatsuki Red Cross Hospital
  • Haruka Yamamoto
  • Tsunetaka Murayama
  • Hiroko Fukata
  • Yasukiyo Nakamura
  • Mami Sonomura
  • Aika Okuno
  • Naoki Kanda
  • Chihiro Watanabe
  • Hideo Kita

It has been less than a decade since immune checkpoint inhibitors became the mainstay of lung cancer treatment, and 2020 saw the advent of the era of complex immune checkpoint inhibitors. Although clinical trials have shown that the therapeutic effects of complex immune checkpoint inhibitors are favorable, they are associated with an increase in adverse events. The use of combined immune checkpoint inhibitors in clinical practice has progressed slowly, and the frequency and types of adverse events they cause remain unclear. Here we report the adverse events of six patients with lung cancer treated with regimens containing nivolumab and ipilimumab in 2021. Four of the six patients had grade 3 or higher adverse events, including one patient with lung injury and one patient with skin injury, both of whom died. The timing and nature of the adverse events were difficult to predict.

Keywords:

Lung Cancer Immune Checkpoint Inhibitors Nivolumab Ipilimumab 9LA Immune-related Adverse Events

References

  1. Cancer Facts & Figures 2020 [Internet]. Atlanta: American Cancer Society; 2020. p. 1–76 [cited 2021 Nov]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf
  2. The editorial board of the Cancer Statistics in Japan (editors). Cancer Statistics in Japan 2021. Tokyo, Japan: Foundation for Promotion of Cancer Research (FPCR); 2021. p. 1–146. Available from: https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2021.pdf).
  3. Reynolds K, Thomas M, Dougan M. Diagnosis and management of hepatitis in patients on checkpoint blockade. The Oncologist 2018; 23(9): 991–997. doi: 10.1634/theoncologist.2018-0174.
  4. Hellmann MD, Paz-Ares L, Caro RB, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. New England Journal of Medicine 2019; 381(21): 2020–2031. doi: 10.1056/NEJMoa1910231
  5. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. The Lancet Oncology 2021; 22(2): 198–211. doi: 10.1016/S1470-2045(20)30641-0
  6. Raschi E, Gatti M, Gelsomino F, et al. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: A clinical perspective from Pharmacovigilance. Targeted Oncology 2020; 15(4): 449–466. doi: 10.1007/s11523-020-00738-6.
  7. Logan IT, Zaman S, Hussein L, et al. Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: A case report and literature review. Journal of Immunotherapy 2020; 43(3): 89–92. doi: 10.1097/CJI.0000000000000302
  8. Gopee NH, Gourley AM, Oliphant TJ, et al. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors. Dermatology Online Journal 2020; 26(8): 1–5. doi: 13030/qt8fc428f6. PMID: 32941713.
  9. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 2019; 17(3): 255–289. doi: 10.6004/jnccn.2019.0013
  10. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. New England Journal of Medicine 2018; 378(2): 158–168. doi: 10.1056/NEJMra1703481.
  11. Woolridge KF, Boler PL, Lee BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis 2018; 101(1): E15–E21. PMID: 29529123
  12. Socinski MA, Nishio M, Jotte RM, et al. IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC. Journal of Thoracic Oncology 2021; 16(11): 1909–1924. doi: 10.1016/j.jtho.2021.07.009
  13. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. New England Journal of Medicine 2018; 378(22): 2078–2092. doi: 10.1056/NEJMoa1801005
  14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine 2019; 381(16): 1535–1546. doi: 10.1056/NEJMoa1910836